The H2 Blockers' Rx-to OTC Switch: For Whom Will It Spell Relief?

DSpace/Manakin Repository

dc.contributor.advisor	Hutt, Peter Barton	en_US
dc.contributor.author	Kisloff, Michelle A.	en_US
dc.date.accessioned	2012-06-07T04:01:00Z
dc.date.issued	1995	en_US
dc.identifier.citation	The H2 Blockers' Rx-to OTC Switch: For Whom Will It Spell Relief? (1995 Third Year Paper)	en
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:8846781
dc.description.abstract	Tylenol. Advil. Monistat 7. Imodium AD. These are some of the most commonly used, widely available, and successful drugs in the United States. All of them began as drugs only available by a prescription. All of them made a successful prescription-only to over-the-counter (Rx-to-OTC) switch through the switch" mechanisms of the Food and Drug Administration (FDA). Due to the amount of money that pharmaceutical companies can make with an Rx-to-OTC switch, the FDA has received dozens of switch requests in the last few years, and it expects to receive many more in the near future.	en
dc.language.iso	en_US	en
dash.license	LAA	en_US
dc.subject	Food and Drug Law	en
dc.subject	H2 blockers	en
dc.subject	HZ blockers	en
dc.subject	Rx to OTC	en
dc.title	The H2 Blockers' Rx-to OTC Switch: For Whom Will It Spell Relief?	en
dc.type	Paper (for course/seminar/workshop)	en_US
dc.date.available	2012-06-07T04:01:00Z